De Novo Ventures

DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would have significant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by investment success in selected medical device and biotechnology companies. With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. They invest in all stages of enterprise development and growth – from early stage to late stage. The unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.

Frederick Dotzler

MD and Co-Founder

RF

Richard Ferrari

MD and Co-Founder

Rich Ferrari

MD and Co-Founder

Joe Mandato

MD

JM

Joseph M. Mandato

MD

94 past transactions

EBR Systems

Venture Round in 2009
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

SynergEyes

Series C in 2009
SynergEyes, Inc., a technology and OD-led contact lens company, manufactures and sells contact lens and other lens for eye care professionals. It offers hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, and irregular cornea conditions. It sells its products through distributors in the United States and internationally. SynergEyes, Inc. was formerly known as Quarter Lambda Technologies, Inc. The company was founded in 2001 and is based in Carlsbad, California.

Ovalis

Series A in 2005
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Astute Medical, Inc.

Series C in 2012
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

TRIA Beauty, Inc.

Venture Round in 2012
TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

Articulinx, Inc.

Series B in 2010
Articulinx offers minimally-invasive implants and devices for the treatment of hand osteoarthritis in the United States. The company’s products are also used in the orthopedic/extremities/and small joints market. Articulinx was founded in 2007 and is based in Cupertino, California.

Simpirica Spine

Series C in 2011
Simpirica Spine was founded in 2006 to develop minimally invasive, flexion-restricting stabilization devices.

HemaQuest Pharmaceuticals

Series B in 2012
HemaQuest Pharmaceuticals, Inc. provides pharmaceutical products. The Company develops small molecule therapeutics to treat serious and life threatening hematologic disorders, including anemia, beta thalassemia, sickle cell anemia, and neutropenia. HemaQuest Pharmaceuticals operates in the United States.

OncoMed Pharmaceuticals

Series B in 2008
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.

EBR Systems

Series A in 2004
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

Spinal Modulation

Series C in 2009
Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

EBR Systems

Series B in 2005
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

Astute Medical, Inc.

Series B in 2010
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

Facet Solutions

Debt Financing in 2009
Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

EndoGastric Solutions, Inc.

Venture Round in 2009
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

Spinal Modulation

Series A in 2006
Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

PhotoThera

Series C in 2006
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

iScience Interventional

Series C in 2003
iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

Pulmonx

Private Equity Round in 2012
Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung. The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.

Avedro

Series D in 2013
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Benvenue Medical

Series B in 2008
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

EndoGastric Solutions, Inc.

Venture Round in 2012
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

PhotoThera

Series B in 2005
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

Spiracur

Series B in 2009
Spiracur Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric.

Paracor Medical

Series D in 2007
Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.

iScience Interventional

Series F in 2009
iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

POINT Biomedical

Private Equity Round in 2008
POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphereâ„¢. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphereâ„¢, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques

WaveTec Vision

Series C in 2009
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

CardioMind

Series C in 2007
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

WaveTec Vision

Venture Round in 2012
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Avedro

Venture Round in 2017
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

InSound Medical

Series E in 2006
InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

Benvenue Medical

Series D in 2012
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Ovalis

Series B in 2007
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Paracor Medical

Series C in 2004
Paracor Medical is an innovative medical device company focused on providing unique, technology-driven solutions for the treatment of heart failure. Founded in 1999, Paracor was established to pursue new and innovative ways to treat heart failure (HF) that would not require the patient to undergo open chest surgery. Paracor engineers recognized that a mechanical approach to reducing the workload of a failing, diseased heart muscle could be a new and effective solution.

Benvenue Medical

Series C in 2011
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Pulmonx

Series B in 2007
Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung. The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.

Bacchus Vascular

Series D in 2003
Bacchus Vascular, Inc. offers medical devices for the treatment of occlusive vascular disease to interventional radiologists and vascular surgeons in the United States. It provides the TRELLIS-8 Peripheral Infusion System, an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted delivery of clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California.

iScience Surgical

Series C in 2005
iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

Cartilix

Series B in 2006
Cartilix develops and commercializes biomaterials to repair damaged tissues in articular joints and other applications. It focuses on a technology for cartilage filling in regenerative medicine. The company was founded in 2004 and is based in Foster City, California.

Renovis

Series B in 2002
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.

InSound Medical

Series E in 2008
InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

EndoGastric Solutions, Inc.

Venture Round in 2012
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

MyoScience

Series E in 2013
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

Spinal Kinetics LLC

Series A in 2004
Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

WaveTec Vision

Series B in 2007
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

WaveTec Vision

Series D in 2011
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California.

Spinal Kinetics LLC

Venture Round in 2014
Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

SynergEyes

Series B in 2006
SynergEyes, Inc., a technology and OD-led contact lens company, manufactures and sells contact lens and other lens for eye care professionals. It offers hybrid contact lenses to transform vision for patients with astigmatism, presbyopia, and irregular cornea conditions. It sells its products through distributors in the United States and internationally. SynergEyes, Inc. was formerly known as Quarter Lambda Technologies, Inc. The company was founded in 2001 and is based in Carlsbad, California.

Sierra Surgical

Series B in 2008
Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

Avedro

Series A in 2008
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

HemaQuest Pharmaceuticals

Series A in 2007
HemaQuest Pharmaceuticals, Inc. provides pharmaceutical products. The Company develops small molecule therapeutics to treat serious and life threatening hematologic disorders, including anemia, beta thalassemia, sickle cell anemia, and neutropenia. HemaQuest Pharmaceuticals operates in the United States.

MicroVention Terumo

Series C in 2001
MicroVention Terumo is a medical device company. It develops catheter-based and minimally-invasive neuroendovascular technologies for cerebral aneurysms and other neurovascular diseases. The company’s products include delivery and detachment systems, access products, intraluminal devices, occlusion balloons, and flow diverters, as well as polymer, platinum, and hydrogel coil products. MicroVention Terumo offers its products through a network of specialty distributors primarily in North America, South America, Europe, Africa, the Middle East, and Asia Pacific. Founded in 1997, MicroVention Terumo is based in Tustin, California. As of March 30, 2006, it operates as a subsidiary of Terumo Corporation.

CD Group

Acquisition in 2016
CD Group, Inc. is a full-service consulting and managed services company, specializing in JD Edwards® and Oracle® enterprise solutions. As an Oracle Platinum Partner, the company is a recognized industry leader with a 24-year history of serving clients throughout North America and internationally. The company provides both project-based and support services across a wide range of technology solutions consisting of enterprise resource planning (ERP), enterprise performance management (EPM), and customer relationship management (CRM).

Astute Medical, Inc.

Series B in 2011
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

TearScience, Inc.

Series B in 2007
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Astute Medical, Inc.

Series A in 2008
Astute Medical, Inc., a life science tools company, discovers and develops protein biomarkers to serve as the basis for novel diagnostic tests for conditions that require rapid diagnosis and risk assessment. The company focuses on prognostic biomarker validation. It offers NephroCheck, a single use cartridge to detect biomarkers of acute kidney injury. The company also provides Astute140, a meter that converts fluorescent signal from NephroCheck test cartridge into a single numerical result. It sells its products in the United States and Europe. Astute Medical, Inc. was founded in 2007 and is based in San Diego, California with a location in Paris, France. As of April 4, 2018, Astute Medical, Inc. operates as a subsidiary of bioMérieux S.A.

Spinal Kinetics LLC

Debt Financing in 2009
Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

EBR Systems

Series D in 2011
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

InSound Medical

Series D in 2004
InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

TearScience, Inc.

Series C in 2010
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Talima Therapeutics

Series B in 2007
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

PhotoThera

Series D in 2009
PhotoThera is currently hiring for the following positions: Sr. Software Engineer Mechanical Engineer Configuration Management Engineer Sr. Electrical Engineer Send your resume and cover letter to ktitano@photothera.com, or go to www.photothera.com for further information. Specialties laser, medical device, eschemic, stroke, infrared

TearScience, Inc.

Series D in 2016
TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was founded in 2005 and is based in Morrisville, North Carolina. As of September 6, 2017, TearScience, Inc. operates as a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Benvenue Medical

Series E in 2014
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

TRIA Beauty, Inc.

Series D in 2007
TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

TRIA Beauty, Inc.

Venture Round in 2011
TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

Spinal Modulation

Series D in 2011
Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

Benvenue Medical

Series F in 2016
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.

Vitreoretinal Technologies

Series A in 2007
Vitreoretinal Technologies, Inc., an ophthalmic biopharmaceutical company, engages in the development and commercialization of therapeutic compounds for the treatment of ophthalmic diseases. The company focuses on vitreoretinal ophthalmic diseases and complications related to ophthalmic surgery. Its products include Vitreosolve, a drug used for the treatment of diabetic retinopathy, as well as to liquefy the vitreous gel prior to vitrectomy surgery; and Neurosolve, a compound used for glaucomatous optic nerve damage progression prevention, dry age related macular degeneration progression, and retinitis pigmentosa treatment.

Spiracur

Series C in 2011
Spiracur Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome for patients and clinicians. Spiracur strives to develop products that are truly patient-centric.

Talima Therapeutics

Series A in 2005
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

iScience Surgical

Series B in 2003
iScience Surgical, Inc. is a privately-held company founded in 1999. It is developing high resolution imaging systems and microsurgical instruments for the treatment of glaucoma. The Company's products are designed to complement existing glaucoma surgical techniques and serve as a platform for a new generation of minimally invasive procedures. Glaucoma is a sight threatening circulatory disorder of the eye that affects approximately 4.2 million Americans and 69 million people worldwide. More than $2 billion is spent annually on glaucoma medications and treatments worldwide, the majority of which are unable to restore the eye's natural drainage process.

iScience Interventional

Venture Round in 2012
iScience Interventionalâ„¢ discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. This new category of therapy is called Interventional Ophthalmology. It encompasses microcatheter-based therapies designed to access a wide range of anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye.

CardioMind

Venture Round in 2008
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.

Sierra Surgical

Series A in 2007
Sierra Surgical Technologies develops minimally invasive surgical systems. The company develops female sterilization technology. Sierra Surgical Technologies, Inc. is based in Palo Alto, California.
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

MyoScience

Series D in 2012
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

EBR Systems

Series C in 2008
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It provides Wireless Cardiac Stimulation of the Left Ventricle System, an endocardial pacing system for cardiac resynchronization therapy, which is a treatment for heart failure that uses an implantable pacemaker to improve the pumping efficiency of the heart by synchronizing the left and right ventricles. The company was founded in 2003 and is headquartered in Sunnyvale, California.

FlowMedica

Series D in 2005
FlowMedica a medical device company, produces intravascular systems for implementing Targeted Renal Therapy. The company offers Benephit CV Infusion System that provides physician-specified therapeutic agents directly into the renal arteries through an infusion catheter while allowing simultaneous coronary procedures through a single vessel access site in the femoral artery; and Benephit XTMini Infusion System that allows for bilateral infusion to the kidneys in patients with smaller vascular anatomies.

InSound Medical

Series E in 2008
InSound Medical, Inc., a privately held, venture-backed company based in Newark, California, develops and manufactures next-generation hearing solutions. Major investors include Johnson & Johnson, DeNovo Ventures, CMEA Ventures, and Psilos Group Managers, LLC.

MyoScience

Series B in 2008
MyoScience Inc. engages in development and commercialization of technology driven dermatological products. MyoScience Inc. was founded in 2005 and is headquartered in Redwood City, California.

AxoGen, Inc.

Post in 2007
AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

HemaQuest Pharmaceuticals

Series B in 2010
HemaQuest Pharmaceuticals, Inc. provides pharmaceutical products. The Company develops small molecule therapeutics to treat serious and life threatening hematologic disorders, including anemia, beta thalassemia, sickle cell anemia, and neutropenia. HemaQuest Pharmaceuticals operates in the United States.
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

TRIA Beauty, Inc.

Private Equity Round in 2013
TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah, Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California.

Spinal Kinetics LLC

Series B in 2006
Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.

Facet Solutions

Series B in 2005
Facet Solutions develops surgical devices for the treatment of degenerative spinal disorders. Facet Solutions was founded on 2003 and is based in Hopkinton, Massachusetts.

Avedro

Series F in 2018
Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Lumend

Series D in 2003
LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.

EndoGastric Solutions, Inc.

Venture Round in 2009
EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. EndoGastric Solutions, Inc. was founded in 2003 and is headquartered in Redmond, Washington.

Pulmonx

Series C in 2010
Pulmonx Corporation, based in Redwood City, Calif., is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. The company is currently engaged in the design, development and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The company’s Zephyr® Endobronchial Valve (EBV) therapy* involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The goal is to reduce the volume of the diseased portions of the lung, allowing increased ventilation to healthier areas of the lung. The company has CE mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System. The company has 510(k) marketing clearance for the Chartis System in the United States.